Monday - March 09, 2026

Category Archives: Pharmaceuticals & Biotech

Rapid Dose (CSE: DOSE) (OTCQB: RDTCF) Global Patent for QuickStrip™ in the $38B Smoke-Free Nicotine Market – Watch TNYA, UOKA, SGN, MMCP Today!

Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral … Continue reading →

Peraso (NASDAQ: PRSO) Surges After Military Drone Identification Breakthrough Watch LRHC, OLOX, DTCK USEG Today!

  Shares of Peraso Inc. (NASDAQ: PRSO) surged into the spotlight Friday after the company announced its 60 GHz millimeter-wave (mmWave) semiconductor technology has been selected for a next-generation military drone Identification Friend or Foe (IFF) system, sending the stock … Continue reading →

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

  As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale. … Continue reading →

Virtuix (NASDAQ: VTIX) In Focus as U.S. Military Adoption and Meta Partnership Fuel VR Growth – Watch RLMD, AGH, PRSO, WTI Today!

  Virtuix Holdings, Inc. (NASDAQ: VTIX) is drawing growing investor attention after the newly listed virtual-reality technology company reported strong revenue growth and expanding adoption across U.S. military training, robotics simulation, and consumer XR gaming platforms. Shares of VTIX surged … Continue reading →

Esophageal Cancer Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Oncolys BioPharma Inc, Genentech, OncoTherapy Science, Shionogi, CStone Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Acute Lymphocytic Leukemia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Cellectis S.A, Autolus Limited, Takara Bio, AbbVies, Janssen LLC

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Lymphocytic Leukemia pipeline constitutes 120+ key companies continuously working towards developing 125+ Acute Lymphocytic Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Tiefenbacher Group’s “Amifampridine” Market size expansion of Several Folds by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Amifampridine (Tiefenbacher Group’s) providing insights into the drug market landscape and market forecast of Amifampridine upto 2034. The report, titled “Amifampridine Sales … Continue reading →

Clostridium Difficile Infections Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Alexion Pharmaceuticals “Eculizumab” Market size expansion of Several Folds by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Eculizumab (Alexion Pharmaceuticals) providing insights into the drug market landscape and market forecast of Eculizumab upto 2034.   [Las Vegas, United States] … Continue reading →